MX2023007023A - Proteinas de inmunoglobulina que se unen a agonistas de npr1. - Google Patents

Proteinas de inmunoglobulina que se unen a agonistas de npr1.

Info

Publication number
MX2023007023A
MX2023007023A MX2023007023A MX2023007023A MX2023007023A MX 2023007023 A MX2023007023 A MX 2023007023A MX 2023007023 A MX2023007023 A MX 2023007023A MX 2023007023 A MX2023007023 A MX 2023007023A MX 2023007023 A MX2023007023 A MX 2023007023A
Authority
MX
Mexico
Prior art keywords
npr1
proteins
bind
certain embodiments
agonists
Prior art date
Application number
MX2023007023A
Other languages
English (en)
Inventor
Neil Stahl
Vishal Kamat
Ashique Rafique
Michael Dunn
Lori Morton
Tammy Huang
Ishita Chatterjee
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023007023A publication Critical patent/MX2023007023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona nuevas proteínas de inmunoglobulina que se unen a un agonista del receptor de péptido natriurético humano 1 (NPR1), preferiblemente un anticuerpo anti-NPR1. En ciertas modalidades, las proteínas de la descripción comprenden al menos un dominio variable de inmunoglobulina que se une a un anticuerpo anti-NPR1. En ciertas modalidades, las proteínas de la descripción son útiles en el bloqueo y/revertir el efecto de un anticuerpo anti-NPR1 administrado. En ciertas modalidades, las proteínas de unión al antígeno son útiles para el manejo efectivo de la presión sanguínea y hemodinámicas en seres humanos.
MX2023007023A 2020-12-18 2021-12-17 Proteinas de inmunoglobulina que se unen a agonistas de npr1. MX2023007023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127959P 2020-12-18 2020-12-18
PCT/US2021/064073 WO2022133239A1 (en) 2020-12-18 2021-12-17 Immunoglobulin proteins that bind to npr1 agonists

Publications (1)

Publication Number Publication Date
MX2023007023A true MX2023007023A (es) 2023-08-29

Family

ID=79687048

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007023A MX2023007023A (es) 2020-12-18 2021-12-17 Proteinas de inmunoglobulina que se unen a agonistas de npr1.

Country Status (12)

Country Link
US (1) US20220195058A1 (es)
EP (1) EP4263616A1 (es)
JP (1) JP2024503784A (es)
KR (1) KR20230132468A (es)
CN (1) CN116964101A (es)
AU (1) AU2021401415A1 (es)
CA (1) CA3202629A1 (es)
CL (1) CL2023001680A1 (es)
CO (1) CO2023009498A2 (es)
IL (1) IL303542A (es)
MX (1) MX2023007023A (es)
WO (1) WO2022133239A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004329A2 (pt) 2018-10-23 2021-08-03 Regeneron Pharmaceuticals, Inc. anticorpos anti-npr1 e usos dos mesmos
AU2022363841A1 (en) * 2021-10-11 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
US20230250170A1 (en) * 2021-12-06 2023-08-10 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US9090695B2 (en) 2008-12-03 2015-07-28 Morphosys Ag Antibodies for guanylyl cyclase receptors
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
BR112021004329A2 (pt) 2018-10-23 2021-08-03 Regeneron Pharmaceuticals, Inc. anticorpos anti-npr1 e usos dos mesmos
AR117343A1 (es) * 2018-12-18 2021-07-28 Novartis Ag AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
MX2021015160A (es) * 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.

Also Published As

Publication number Publication date
US20220195058A1 (en) 2022-06-23
CL2023001680A1 (es) 2024-03-08
CO2023009498A2 (es) 2023-08-28
WO2022133239A1 (en) 2022-06-23
IL303542A (en) 2023-08-01
CN116964101A (zh) 2023-10-27
AU2021401415A1 (en) 2023-07-13
KR20230132468A (ko) 2023-09-15
EP4263616A1 (en) 2023-10-25
CA3202629A1 (en) 2022-06-23
JP2024503784A (ja) 2024-01-29

Similar Documents

Publication Publication Date Title
MX2023007023A (es) Proteinas de inmunoglobulina que se unen a agonistas de npr1.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PH12021550255A1 (en) Anti-npr1 antibodies and uses thereof
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
EA202190542A1 (ru) Сконструированные биспецифические белки
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
NZ596409A (en) Anti macrophage migration inhibitory factor antibodies
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
CO6230996A2 (es) Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3
WO2022031884A3 (en) Il2rg binding molecules and methods of use
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2020002880A (es) Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).
MX2023001491A (es) Moleculas de union a gp130 y metodos de uso.
MX2021007093A (es) Anticuerpos btla.
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)
MX2022007855A (es) Anticuerpos hvem anti-humano (tnfrsf14) y usos de los mismos.
MX2022003465A (es) Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения